Alnylam

Blackstone finalizes R&D pact with Alnylam as part of earlier $2 billion investment
Blackstone finalizes R&D pact with Alnylam as part of earlier $2 billion investment
Endpoints
Blackstone
Alnylam
R&D
Flag link:
Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show
Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show
Fierce Pharma
Alnylam
RNAi
Givlaari
acute hepatic porphyria
Flag link:
Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data
Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data
Endpoints
Alnylam
clinical trials
RNAi
lumasiran
PH1
Flag link:
Alnylam nabs speedy review, setting up 3rd possible approval in 3 years
Alnylam nabs speedy review, setting up 3rd possible approval in 3 years
Endpoints
Alnylam
RNAi
FDA
drug approvals
lumasiran
hyperoxaluria
Flag link:
Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral
Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral
Fierce Biotech
Alnylam
Vir Biotechnology
COVID-19
RNAi
clinical trials
Flag link:
Alnylam's vutrisiran gets fast-track treatment at the FDA
Alnylam's vutrisiran gets fast-track treatment at the FDA
Fierce Biotech
Alnylam
RNAi
FDA
hATTR
vutrisiran
fast track
Flag link:
Blackstone backs Alnylam with up to $2B investment
Blackstone backs Alnylam with up to $2B investment
BioPharma Dive
generics
Alnylam
Blackstone
RNAi
Flag link:
Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1
Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1
Pharmaceutical Business Review
Alnylam
Primary Hyperoxaluria
FDA
lumasiran
Flag link:
After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration
After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration
Endpoints
Alnylam
Dicerna
John Maraganore
Douglas Fambrough
RNAi
Merck
Flag link:
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Pharmaceutical Business Review
Vir Biotechnology
Alnylam
COVID-19
RNAi
drug development
Flag link:
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)
Pharmaceutical Business Review
Alnylam
RNAi
Gen
Onpattro
Turkey
hATTR amyloidosis
Flag link:
Alnylam, Vir team up to develop siRNAs to tackle COVID-19
Alnylam, Vir team up to develop siRNAs to tackle COVID-19
Fierce Biotech
Alnylam
Vir Biotechnology
RNAi
coronaviruses
COVID-19
siRNA
Flag link:
Ex-Sanofi chief Olivier Brandicourt, current Blackstone advisor, jumps on Alnylam board
Ex-Sanofi chief Olivier Brandicourt, current Blackstone advisor, jumps on Alnylam board
Endpoints
Sanofi
Olivier Brandicourt
Alnylam
Flag link:
With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans
With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans
BioSpace
drug pricing
Roche
Eli Lilly
Amgen
Alnylam
Sanofi
Flag link:
JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval
JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval
Fierce Pharma
Alnylam
RNAi
Givlaari
John Maraganore
JPMHC 2020
Flag link:
3 Rare Disease Drug Launches to Watch in 2020
3 Rare Disease Drug Launches to Watch in 2020
Motley Fool
Global Blood Therapeutics
sickle cell disease
Oxbryta
Novartis
SCD
Adakveo
Alnylam
Givlaari
acute hepatic porphyria
FDA
Flag link:
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
Biopharma Dive
Alnylam
lumasiran
clincial trials
RNAi
kidney disease
Primary Hyperoxaluria
Flag link:
5 New Drug Approvals the FDA Gave Top Priority
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
FDA
drug approvals
Global Blood Therapeutics
Oxbryta
Alnylam
Givlaari
BeiGene
Brukinsa
Vertex Pharmaceuticals
Flag link:
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
FDA
Vertex Pharmaceuticals
Trikafta
Novartis
Adakveo
Alnylam
Givlaari
BeiGene
Brukinsa
Global Blood Therapeutics
Oxbryta
drug approvals
Flag link:
Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class
Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class
Motley Fool
RNAi
Givlaari
Alnylam
Flag link:

Pages